rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Solventum Corporation

SOLV · NYSE

Health CareMedical DevicesLeading

SOLV stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 11 weeks. It is 8.8% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$201K
Insider sales, 12 months
$0
Officials’ trades on record
11
Institutions holding
822 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$623.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

11 disclosed lines: House 2, Senate 5, executive 4; 7 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k11 May 2026filed 1 Jul 2026
Alan Armstrong Senate: U.S. Senate eFDSenatorbought$1k–$15k27 Mar 2026filed 21 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k26 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k17 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k12 Feb 2026filed 14 May 2026
J. French Hill House: U.S. House ClerkAR02sold$15k–$50k31 Dec 2025filed 23 Jan 2026
Ron Wyden Senate: U.S. Senate eFDSenatorsoldspouse$1k–$15k6 Feb 2025filed 21 Feb 2025
Julie Johnson House: U.S. House ClerkTX32soldjoint$1k–$15k15 Jan 2025filed 12 Feb 2025
Gary C. Peters Senate: U.S. Senate eFDSenatorsold$1k–$15k14 May 2024filed 23 May 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k3 May 2024filed 5 Aug 2026
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k3 May 2024filed 14 Jun 2024

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Amy McBride WendellDirectorbought1,475at $68.0310 Mar 2026filed 11 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders822+6 on the quarter
New · exited121 · 115
Reported value$9.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Independent Franchise Partners LLPadded · filed 13 Aug 202616,170,038$1.2B+436,543+2.8%
BlackRock, Inc.reduced · filed 7 Aug 20269,761,863$753.1M-717,109−6.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20269,624,829$742.6M+22,880+0.2%
TRIAN FUND MANAGEMENT, L.P.unchanged · filed 12 Aug 20268,236,753$635.5M00.0%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20266,328,641$488.3M-61,723−1.0%
Davis Selected Advisersreduced · filed 11 Aug 20266,307,729$486.7M-22,596−0.4%
STATE STREET CORPreduced · filed 7 Aug 20265,639,230$435.1M-768,250−12.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,910,624$378.3M+158,364+3.3%
Boston Partnersadded · filed 4 Aug 20264,037,963$311.5M+123,872+3.2%
Invesco Ltd.reduced · filed 14 Aug 20263,309,915$255.4M-479,968−12.7%
31 Mar 2024 – 30 Jun 2026
84462840Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Bryan C. Hanson Company insiderChief Executive Officer · last 1 Sep 20260 · 0
Neil Craig Zieselman Company insiderSVP, Controller & CAO · last 17 Aug 20260 · 0
Amy McBride Wendell Company insiderDirector · last 15 May 20261 · 0
Bernard A. Harris Jr. Company insiderDirector · last 15 May 20260 · 0
Carlos Alban Company insiderDirector · last 15 May 20260 · 0
Carrie Smith Cox Company insiderDirector · last 15 May 20260 · 0
Darryl L. Wilson Company insiderDirector · last 15 May 20260 · 0
Elizabeth Mily Company insiderDirector · last 15 May 20260 · 0
Glenn A. Eisenberg Company insiderDirector · last 15 May 20260 · 0
John H. Weiland Company insiderDirector · last 15 May 20260 · 0
Karen J. May Company insiderDirector · last 15 May 20260 · 0
Shirley Ann Edwards Company insiderDirector · last 15 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$19K
Latest24 Sep 2026

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202553.5%
Operating profit marginFY 2025 · to 31 Dec 202526.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-0.1%
Return on capital employedFY 2025 · to 31 Dec 202519.5%
Cash conversionFY 2025 · to 31 Dec 202523.7%
Debt to equityFY 2025 · to 31 Dec 20251.00×
Research spendFY 2025 · to 31 Dec 20258.9%
Share count trendFY 2025 · to 18 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$878.0M
Free cash flowFY 2025 · to 31 Dec 2025−$10.0M

Analyst forecasts

No analyst forecasts yet.